Emily Rhoades
Nurse Practitioner · Wilmington, NCNPI 1205529047
Payments from drug & device makers
Across 148 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$600
- Lilly USA, LLC$456
- Novo Nordisk$338
- AstraZeneca$299
- Pfizer$249
- Otsuka America Pharmaceutical, Inc.$135
- plus $646 from 18 others
What the payments were for
- Food & beverage$2,67798%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $600 |
| Lilly USA, LLC | 27 | $456 |
| Novo Nordisk | 20 | $338 |
| AstraZeneca | 17 | $299 |
| Pfizer | 11 | $249 |
| Otsuka America Pharmaceutical, Inc. | 5 | $135 |
| Exact Sciences | 5 | $89 |
| Amgen | 4 | $75 |
| Halozyme Inc | 3 | $70 |
| Boehringer Ingelheim | 2 | $53 |
| GSK | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Corium, LLC | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Merck | 1 | $26 |
| Astellas Pharma US Inc | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Neos Therapeutics, LP | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
How this compares
$2,722 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $90,329 |
| MounjaroTirzepatide | 32 | $34,782 |
| JardianceEmpagliflozin | 44 | $27,848 |
| Repatha SureclickEvolocumab | 28 | $24,037 |
| FarxigaDapagliflozin Propanediol | 13 | $15,325 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $14,320 |
| EliquisApixaban | 18 | $11,564 |
| PaxlovidNirmatrelvir/Ritonavir | 13 | $2,858 |
| Rosuvastatin Calcium | 230 | $2,736 |
| Duloxetine Hcl | 51 | $2,463 |
| SynthroidLevothyroxine Sodium | 35 | $2,440 |
| Telmisartan | 44 | $2,134 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $1,776 |
| ValacyclovirValacyclovir Hcl | 24 | $1,717 |
| Potassium Chloride | 30 | $1,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $338 | $90,32983 claims |
| Lilly USA, LLCMounjaro | $456 | $34,78232 claims |
| Boehringer IngelheimJardiance | $53 | $27,84844 claims |
| AstraZenecaFarxiga | $299 | $15,32513 claims |
| PfizerEliquis, Paxlovid | $249 | $14,42231 claims |
| GSKTrelegy Ellipta | $47 | $14,32015 claims |
| AbbVieSynthroid | $600 | $2,44035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Wilmington
- Bridgette WilliamsWilmington$35K
- Kelly GlissonWilmington$30K
- Lauren GardnerWilmington$28K
- Michelle StoughWilmington$24K
- Edith SaffoWilmington$19K
- Rebecca MaphisWilmington$18K
- Breanna BrousseauWilmington$12K
- Anna PaylorWilmington$11K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.